Is Novavax a Buy Before Nov. 3?
Novavax (NASDAQ: NVAX) has climbed the most of any other healthcare company so far this year. Shares have soared more than 2,160% as the clinical stage biotech business has advanced its coronavirus vaccine candidate through trials and won a whopping $1.6 billion from the U.S. government to support its program.
The U.S. government has played a major role in the coronavirus vaccine race so far. Through Operation Warp Speed (OWS), the government has offered vaccine developers billions of dollars in an effort to bring a vaccine to market by January. Now, word on the street is that a launch may come even sooner. The Centers for Disease Control and Prevention (CDC) recently advised states to prepare for a possible vaccine rollout as soon as late October, according to news reports. That means a vaccine would be available before the presidential election on Nov. 3. Considering the timeline, let's take a look at whether it's a good idea to buy shares of Novavax before that day comes.
Source Fool.com